A Phase 1 Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients with Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy with Temodar® in Patients with Glioblastom Multiforme
The purpose of this study is to determine the safety and tolerability of the study drug (CTO) when given to patients with advanced or metastatic solid tumors.
Multiple disease sites
*Subjects should have advanced or metastatic solid tumors for which there is no standard therapy;
*Subjects must have received prior anticancer therapy or not be eligible for any established convential therapy;
*Subjects must be men or women 18 years or older;
* Subjects may not have had prior treatment 4 week prior to study entry.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Tactical Therapeutics, Inc./INDUSTRY